Molecular targeted therapy in ovarian cancer: what is on the horizon? - Wikidata - wikimedia - TriplyDB

Molecular targeted therapy in ovarian cancer: what is on the horizon?

Molecular targeted therapy in ovarian cancer: what is on the horizon?

http://www.wikidata.org/entity/Q37888659

about

Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles.Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer Inhibition of ovarian cancer proliferation and invasion by pachymic acid.The role of secondary cytoreductive surgery in patients with recurrent epithelial ovarian, tubal, and peritoneal cancers: a comparative effectiveness analysis Advantages of the avian model for human ovarian cancer Ovarian cancer molecular pathology.Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors.Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.

P2860

Q30570691-1778E2B6-FE8A-4EFB-AB62-7B6EE4E9D06B Q33787214-1D0B77CD-C36F-4561-A66A-385CF1E713BB Q35406457-48B90F18-60BF-473D-940B-7E9A3E4B2E38 Q36051531-667D6100-4FFC-48C6-9604-28E39DD771B1 Q36334681-55026654-71FA-4844-A7BF-C2C49B9E2659 Q38021356-C5EB7956-6942-4A42-998A-A72ECEB50271 Q47169877-78D48563-4E2B-492E-A274-46E691DABFE9 Q54979642-FD556170-14CC-4D87-B5BA-7A390DD3F9B2

P2860

Molecular targeted therapy in ovarian cancer: what is on the horizon?

http://www.wikidata.org/entity/Q37888659

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Molecular targeted therapy in ovarian cancer: what is on the horizon?

@en

Molecular targeted therapy in ovarian cancer: what is on the horizon?

@nl

type

label

Molecular targeted therapy in ovarian cancer: what is on the horizon?

@en

Molecular targeted therapy in ovarian cancer: what is on the horizon?

@nl

prefLabel

Molecular targeted therapy in ovarian cancer: what is on the horizon?

@en

Molecular targeted therapy in ovarian cancer: what is on the horizon?

@nl

P1433

Q37888659-E4E4A6BF-7AC5-4F00-85C2-94657203CCB2

P1476

Q37888659-5B3EEB23-3CEC-425B-BE58-B366ADFF025D

P2093

Q37888659-CCC2BF7D-B60B-47DC-BB53-9ACCED8E4F72

Q37888659-D0F47934-3C96-4FF7-A8A3-580FF7BFB56E

Q37888659-D4018DD2-B9E5-4ACA-84E1-2B540A654AD7

P2860

Q37888659-02989C2C-2B81-4D21-84D1-875E8755E681

Q37888659-070DE9BA-FD51-4E49-8450-17B8F00F8D2E

Q37888659-0895D79D-E1D0-4B33-9142-D792BE8F1D30

Q37888659-118DF0C3-89E1-4EC8-B388-51AEEF2E650B

Q37888659-11CF64F1-58CF-461E-BDE2-FE138FEC296B

Q37888659-12CF81A9-2AB6-4810-81B0-4388044C71A9

Q37888659-221EE075-850C-4E81-A274-D92DD69E9F8A

Q37888659-2462A42F-F89B-45A2-A817-6051EB89C65D

Q37888659-24B1AA88-E320-4C84-B3CC-9CE2E4E4517A

Q37888659-271B2D34-7957-4CC8-8F36-7440F1E94775

P2888

Q37888659-184FBED4-CFC9-4A5A-B0A0-67CDAD428B98

P304

Q37888659-E9880F43-F575-4278-8FF9-CC30C1ADD211

P31

Q37888659-79DDCDBD-5A5A-4C28-A456-1A2B62FF4170

P356

Q37888659-16C58A3B-1140-4A04-AFC3-B3C88BDDE164

P433

Q37888659-A96696E9-CB99-4B74-B8A2-7F9859ADC835

P478

Q37888659-4EE77B82-DDD9-4DB9-9839-140CB7AD8BAB

P577

Q37888659-8FB82569-E0AA-455A-BCC6-A0AA0D9C313D

P6179

Q37888659-2E1A0AF9-1A12-478C-B001-24A22FA59EB4

P698

Q37888659-463CC847-8DAC-4BDB-85DB-071AC30C0677

P921

Q37888659-BA2CF931-6E3C-4B57-BD75-67CCBBDC64DE

P356

11591740-000000000-00000

P1433

P1476

Molecular targeted therapy in ovarian cancer: what is on the horizon?

@en

P2093

Bryan T Hennessy

http://www.w3.org/2001/XMLSchema#string

Maurie Markman

http://www.w3.org/2001/XMLSchema#string

Roshni Kalachand

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion

Protein kinase C iota: human oncogene, prognostic marker and therapeutic target

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Cancer statistics, 2010

Tumor angiogenesis: therapeutic implications

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer

Cancer statistics, 2001

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

P2888

11591740-000000000-00000

P304

947-967

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11591740-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1046763920

http://www.w3.org/2001/XMLSchema#string

P698

21668036

http://www.w3.org/2001/XMLSchema#string

P921